Drug Trial Radar · NCT03516214
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Apr 25, 2018
Primary completion
Sep 30, 2022
Study completion Nov 27, 2023
Sponsor
- Lead sponsor
- University of CologneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 4, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D), to define pharmacokinetic (PK) parameters and the preliminary efficacy of a continuous treatment with EGF816 and trametinib in locally advanced or metastatic (stage IIIB or IV) lung cancer patients with activating mutations in the epithelial growth factor receptor (EGFR).
Conditions
- Bronchial Neoplasms
Interventions
EGF816Drug
Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.
TrametinibDrug
Continuous oral treatment (once daily) with the MEK inhibitor trametinib.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting-toxicities (DLT) of the combination of EGF816 and trametinib to assess the maximum tolerated dose (MTD)/recommended phase II dose (RP2D)Time frame: Approximately one and a half years (from FPFV until the end of the DLT period of the last patient included into the trial or until death of the last patient, whichever occurs first)
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
University Hospital of Cologne
Cologne, Germany
University Hospital Dresden
Dresden, Germany
University Hospital Essen
Essen, Germany
University Hospital Frankfurt
Frankfurt, Germany
University Hospital Würzburg
Würzburg, Germany
Instituto Oncológico Dr. Rosell
Barcelona, Spain
Vall d'Hebron University Hospital
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.